Background Vinflunine (VFL) is a bifluorinated tubulin-targeted agent of the vinca alkaloids
class active in advanced stage breast cancer. We conducted a phase I study combining VFL …

Vinfunine (VFL) is a novel bifluorinated tubulin-targeted agent of the vinca alkaloids class
active in advanced stage breast cancer. We conducted a phase I study combining VFL with …

Introduction: Breast cancer is the most frequently diagnosed cancer and the highest cause of
cancer mortality in females worldwide. The development of drugs improving overall survival …

PURPOSE: This open label phase II study evaluated the safety and efficacy of vinflunine in
patients with breast cancer previously treated with a vinorelbine-based regimen and who …

1043 Background: Vinflunine (VFL) is a new and innovative microtubule inhibitor of the
vinca alkaloid class that achieves high intracellular concentrations. By inhibition of tubulin …

Background There is no standard treatment after progression on second-line chemotherapy
for metastatic breast cancer (MBC). We compared vinflunine with physician's choice of …

1031 Background: There is currently no consensus on the efficacy of chemotherapy (CT)
beyond 3rd line in MBC and only eribulin (which has been recently approved) has shown to …

Purpose A phase I study was performed to determine the maximal tolerated dose (MTD),
recommended dose (RD), safety and efficacy of vinflunine when combined with …

Objective: A multicenter, open-label, phase 2 study evaluated the efficacy and safety of
intravenous vinflunine as third-line treatment in patients with progressing metastatic breast …

To evaluate the single agent activity, pharmacokinetics and tolerability of the novel tubulin
targeted agent vinflunine (VFL)(320 mg m− 2 q 21 days) as second-line chemotherapy in …